The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy

Table 2

Changes of HBV markers during therapy.

Item	0 w			12 w			24 w			36 w			48 w
	PEG-IFN group	ETV group	value	PEG-IFN group	ETV group	value	PEG-IFN group	ETV group	value	PEG-IFN group	ETV group	value	PEG-IFN group	ETV group	value
Mean ± SD; HBsAg level (log10 IU/mL)			0.280			0.004			0.003			0.040			0.132
HBV DNA load (log10 IU/mL)			0.127			0.000			0.175			0.143			0.174
HBeAg; Concentration (PEIU/mL); (Q1, Q3)	878.33 (432.55, 1397.77)	1066.62 (489.97, 1401.07)	0.472	52.07 (5.92, 381.71)	57.62 (13.91, 645.96)	0.155	17.02 (2.45, 70.52)	35.52 (6.48, 317.82)	0.039	13.31 (0.72, 49.70)	59.32 (4.51, 206.61)	0.622	7.65 (0.92, 25.32)	16.85 (2.60, 42.85)	0.575
Median; ALT level (U/L); (Q1, Q3)	252.80 (128.95, 356.96)	222.45 (114.10, 344.03)	0.949	68.20 (49.45, 83.23)	33.30 (21.30, 49.80)	0.001	44.86 (25.87, 63.59)	23.12 (17.77, 32.89)	0.004	33.60 (28.15, 55.90)	22.80 (15.25, 25.85)	0.069	33.15 (17.34, 46.73)	20.12 (15.40, 28.98)	0.255

HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; ALT: alanine aminotransferase; value: PEG-IFN group vs. ETV group.